EMA Authorised: Inaqovi (cedazuridine;decitabine) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

EMA has authorised Inaqovi (cedazuridine/decitabine) for leukemias with myeloid involvement, expanding available treatment options.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myeloid Leukemia

Drugs mentioned

• Cedazuridine-Decitabine (cedazuridine-decitabine)
• INAQOVI (cedazuridine; decitabine)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 19/06/2026